Sole Bookrunner, Broker and Nominated Adviser to Arecor Therapeutics
-
News
Read
Panmure Gordon is delighted to have acted as sole Bookrunner, Broker and Nominated Adviser to Arecor Therapeutics on their recent placing to raise £6.0 million and acquisition of Tetris Pharma, a commercial stage speciality pharmaceutical company.
The proceeds of the Placing will be used to support the acquisition of Tetris Pharma which will add a key commercial diabetes product to Arecor’s portfolio and will help realise Arecor’s vision of becoming a significant self-sustaining biopharmaceutical business.”
Panmure Gordon team includes:
Freddy Crossley, Emma Earl and Mark Rogers – Investment Banking Division
Rupert Dearden – Corporate Broking
David Cox – Specialist Sales
Julie Simmonds – Research
Emma Earl
Managing Director, Healthcare, Investment Banking
Freddy Crossley
Managing Director, Head of Healthcare
Rupert Dearden
Managing Director, Corporate Broking Services
David Cox
Director, Healthcare Specialist